Sorrento Therapeutics, Inc.
SRNE
SRNE was delisted on the 22nd of February, 2023.
4 hedge funds and large institutions have $20 invested in Sorrento Therapeutics, Inc. in 2025 Q3 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
233% more capital invested
Capital invested by funds: $6 → $20 (+$14)
100% more funds holding
Funds holding: 2 → 4 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OC
Oakworth Capital
Birmingham,
Alabama
|
+$1 |
Top Sellers
SRNE Hedge Fund Activity: Q3 2025 in Review
4 of the 7,620 institutional investors tracked by Wall St. Rank reported a position in Sorrento Therapeutics, Inc. (SRNE) for Q3 2025, worth a combined $20 — up 233% from $6 a quarter earlier.
Buyers outnumbered sellers: 3 funds opened new SRNE positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Oakworth Capital, opening a new position worth an estimated $1.
- 4 institutional investors held Sorrento Therapeutics, Inc. (SRNE) as of Q3 2025, up from 2 in Q2 2025.
- Funds reported $20 of Sorrento Therapeutics, Inc. stock for Q3 2025, up 233% quarter-over-quarter.
- 3 funds opened new Sorrento Therapeutics, Inc. positions in Q3 2025 and 0 closed out, a net change of +3 holders.
- The largest Sorrento Therapeutics, Inc. buyer in Q3 2025 was Oakworth Capital, an estimated $1 added.
Based on aggregated 13F filings for Q3 2025.